Regulatory Clearance of the Glide Control Strategy for Upper Limb Prostheses
NCT: NCT06539936 · RECRUITING
Brief Summary
The investigators will test the following hypothesis: Use of Glide results in improved functional performance, satisfaction, and usage metrics as compared to use of a standard Direct Control (DC) prosthesis. This study will compare the use of Glide \[Experimental\] prosthesis with a DC \[Standard\] prosthesis in a clinical setting and in unsupervised daily activity. We will follow a multiple baseline design, specifically an AB design. Each of the subjects will use the Experimental and Standard systems over a total of 24-weeks. The A phase is the baseline phase where the DC prosthesis will be used, and the B phase will be the treatment phase where the Glide prosthesis will be used. Participants will undergo an A phase of either 10-weeks, 12-weeks, or 14-weeks duration, with the remaining 14-, 12-, or 10-weeks of the study being dedicated to the B phase.
Frequently Asked Questions
What is Regulatory Clearance of the Glide Control Strategy for Upper Limb Prostheses?
Regulatory Clearance of the Glide Control Strategy for Upper Limb Prostheses is a clinical trial registered under NCT06539936. Current status: RECRUITING.
What is the status of NCT06539936?
The current status of NCT06539936 (Regulatory Clearance of the Glide Control Strategy for Upper Limb Prostheses) is: RECRUITING.
When did Regulatory Clearance of the Glide Control Strategy for Upper Limb Prostheses start?
Regulatory Clearance of the Glide Control Strategy for Upper Limb Prostheses started on 2024-09-16.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.